Attention deficit

The9 Signed a Definitive Share Purchase Agreement to Invest in GenAI LLM Digital Precision Medicine Platform for Brain Disease WM Therapeutic

Retrieved on: 
Tuesday, March 26, 2024
Diagnosis, Depression, Sleep, The9, Synthetic media, Annual report, Myenteric plexus, Agreement, Disease, Alzheimer's disease, Central nervous system, Attention deficit, Bipolar disorder, Anxiety, AI, IPO, Insurance, Sympathetic nervous system, LLM, Drug development, WM, Spectrum, Good, Generative, Pharmaceutical industry

SHANGHAI, March 26, 2024 /PRNewswire/ -- The9 Limited (Nasdaq: NCTY) ("The9"), an established Internet company, today announced that it signed a definitive share purchase agreement (the "Agreement") with WM Therapeutic Co., Ltd. ("WM Therapeutic"), a company operating Generative AI (GenAI) large language model (LLM) multi-dimensional and multi-omics digital precision medicine platform for brain disease, to purchase an additional 21.7% shares of WM Therapeutic by cash and issuance of The9's restricted shares.

Key Points: 
  • SHANGHAI, March 26, 2024 /PRNewswire/ -- The9 Limited (Nasdaq: NCTY) ("The9"), an established Internet company, today announced that it signed a definitive share purchase agreement (the "Agreement") with WM Therapeutic Co., Ltd. ("WM Therapeutic"), a company operating Generative AI (GenAI) large language model (LLM) multi-dimensional and multi-omics digital precision medicine platform for brain disease, to purchase an additional 21.7% shares of WM Therapeutic by cash and issuance of The9's restricted shares.
  • With the signing of this Agreement, The9 will own 30% of WM Therapeutic.
  • The9 is also granted a purchase option to purchase up to 51% of the total shares of WM Therapeutic under certain conditions.
  • WM Therapeutic develops GenAI large language model brain disease screening platform and digital human personalized psychological consultant, AI precision diagnostic equipment, personalized neuromodulation treatment equipment, Generative AI large language model and AI drug clinical research platform.

EEG Analysis and Animal Behavior in CNS Drug Development, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Wednesday, October 4, 2023
Epilepsy, Central nervous system, Depression, Schizophrenia, Electroencephalography, Neuropharmacology, Attention deficit hyperactivity disorder predominantly inattentive, Non-24-hour sleep–wake disorder, Neuroscience, Toxicity, Biomarker, Doctor of Philosophy, CNS, Attention deficit, Pain, Risk, EEG, Drug discovery, Alzheimer's disease, Medical imaging, Pharmaceutical industry, Generic drug

TORONTO, Oct. 4, 2023 /PRNewswire-PRWeb/ -- EEG analysis (Electroencephalography) is becoming a promising translatable biomarker for predicting the likelihood that novel therapies and compounds will exhibit clinical efficacy early in preclinical development.

Key Points: 
  • In this free webinar, gain insights into electroencephalography (EEG) analysis as physiological endpoints to facilitate drug discovery, lead optimization or candidate compound selection as well as to serve for go/no go decisions.
  • The featured speaker will share case studies of EEG-based signatures in correlation with animal behavior which potentially may validate the EEG as endpoints for a set of translatable biomarkers bridging preclinical and clinical programs.
  • EEG-based signatures represent promising preclinical screens to quickly determine CNS penetration, drug-target engagement, evidence of efficacy, pharmacokinetic/pharmacodynamic profile, CNS safety and toxicity and pro-convulsant risk.
  • Join this webinar to gain insights into EEG analysis as physiological endpoints to facilitate drug discovery for CNS diseases.

Akili Releases EndeavorOTC™ on Android™ Devices, Expanding Treatment Access for Millions of Adults with ADHD

Retrieved on: 
Thursday, September 21, 2023
Technology, Mobile, Wireless, Electronic Games, Men, Health, Entertainment, Consumer, Apps, Applications, Mental Health, Medical Devices, Software, Women, Clinical Trials, Consumer Electronics, Drug, Focus, Drug Enforcement Administration, Habit, Pixel, Clinical trial, ADHD, Quality of life, Android, Attention, Attention deficit, Self-perceived quality-of-life scale, DEA, Patient, ACS, Apple, Samsung Galaxy, FDA, Regulation of tobacco by the U.S. Food and Drug Administration, Internal, Food, Mobile phone, Dietary supplement, Yolo Akili

EndeavorOTC is built on the same technology as Akili’s EndeavorRx®, the world’s first and only FDA-authorized video game treatment, for children 8-12 years old with ADHD.

Key Points: 
  • EndeavorOTC is built on the same technology as Akili’s EndeavorRx®, the world’s first and only FDA-authorized video game treatment, for children 8-12 years old with ADHD.
  • In a recent clinical trial, EndeavorOTC significantly improved focus, attention, and overall quality of life in adults struggling with ADHD symptoms.
  • “Video games are an established part of life for the majority of American adults,” said Jon David, chief product officer of Akili.
  • “By delivering an ADHD treatment via video game, we believe we’re tapping into established habits and making a clinically-proven treatment more accessible and approachable than ever before.

Done., Patient Advocates, and Stakeholders Call For Vital Patient Access To Telehealth

Retrieved on: 
Thursday, October 20, 2022
Online, Suicide, Congress, Time, United States Senate Commerce Subcommittee on Communications, Media, and Broadband, Kaiser Permanente, Technology, White House, Partner, Public health, Gaps, Attention, Venable LLP, Policy, COVID, Drug, DEA, ADHD, Patient, United States House Energy Subcommittee on Health, Consumer protection, Depression, White, Telehealth, Attention deficit hyperactivity disorder predominantly inattentive, PHE, Public health emergency, Awareness, Venable, Rocketplane Global Inc., UCLA, Drug Enforcement Administration, Interstate Commerce Committee, World Mental Health Day, Substance-related disorder, Founder, Adult, Safety, Letter, Management, Anxiety, Travel, Communication, Attention deficit, Prescription, Physical, Pharmaceutical industry, Medicine, Done, Health

WASHINGTON, Oct. 20, 2022 /PRNewswire-PRWeb/ -- The founder of Done. Global Inc., a leading telehealth provider of services for people with attention-deficit/hyperactivity disorder (ADHD), joined renowned medical experts, patients, and a former member of Congress during a policy briefing to advocate for regulatory relief that would permanently allow some clinicians to prescribe medications online without the need to meet in person.

Key Points: 
  • Generally, to prescribe controlled substances via telehealth a provider has to first have had an in-person encounter with the patient.
  • However, the in-person requirement has been suspended during the declared federal Public Health Emergency but could be changed at any time.
  • and board-certified psychiatrist from UCLA who previously worked at institutions like Kaiser Permanente; and the Founder of Done.
  • "Telehealth has been groundbreaking for many patients who do not have easy access to doctors, never mind specialty providers," said Dr. Martinez.

Lenire Biosciences Completes License Agreement with University College London for VSN16R, A Novel Clinical Candidate Treatment for Fragile X Syndrome

Retrieved on: 
Thursday, June 16, 2022
Multiple sclerosis, Myalgia, Spasticity, Patent, Therapy, Attention deficit hyperactivity disorder predominantly inattentive, Attention, Learning, 2009 Davis Cup, University College London, Anxiety, Residential treatment center, Technology, Cincinnati, Attention deficit, Company, Cincinnati Children's Hospital Medical Center, Human, Research, BK, Professor, Autism, UCL Business, Psychiatry, Intellectual disability, Patient, Biomedical Research, UCL, Attention deficit hyperactivity disorder, Disorder, SAN, FXS, Fragile X syndrome, GLOBE, Prevalence, Syndrome, Pharmaceutical industry

The development of this technology was supported by UCL Business (UCLB), the commercialization company of UCL.

Key Points: 
  • The development of this technology was supported by UCL Business (UCLB), the commercialization company of UCL.
  • FXS is a rare, inherited condition that can cause issues including developmental delays, learning and behavioural difficulties, physical abnormalities, anxiety, attention or hyperactivity disorders and autism spectrum disorder.
  • FXS is the most prevalent inherited form of intellectual disability and a leading cause of autism spectrum disorder.
  • Lenire Biosciences is privately held, clinical stage biopharmaceutical company that is developing novel, patent protected therapeutics for the treatment of Fragile X Syndrome (FXS), a leading cause of intellectual disability world-wide that also presents with anxiety, attention deficit, hyperactivity, autism spectrum behaviors and other disabling symptoms.

Reservoir Announces Publishing Deal With Award-Winning, Multi-Platinum and #1 Hit Writer-Producer Oak Felder, Expanding on Existing Joint Venture

Retrieved on: 
Tuesday, February 1, 2022
Honey, Music, Grammy Award for Best R&B Song, Warren, Female, Fire, NASDAQ, Grammy Awards, Kehlani, Chrysalis Records, Founder, Alessia, Billboard, Global Creativity Index, Goal, Lizzo, Dancing with the Devil... the Art of Starting Over, Milk, International, Partnership, Love, Student, Philly Groove Records, Felder, Rolling Stone, GLOBE, Reservoir, Orphanage, Knowledge, Demi Lovato, Sport, Harvard University, Attention deficit, Hotel manager, Pop & Oak, Bigger Love

NEW YORK, Feb. 01, 2022 (GLOBE NEWSWIRE) -- Reservoir Media, Inc. (NASDAQ: RSVR) (Reservoir or the Company), an award-winning independent music company, today announced a worldwide publishing deal with #1 hit writer-producer Warren Oak Felder.

Key Points: 
  • NEW YORK, Feb. 01, 2022 (GLOBE NEWSWIRE) -- Reservoir Media, Inc. (NASDAQ: RSVR) (Reservoir or the Company), an award-winning independent music company, today announced a worldwide publishing deal with #1 hit writer-producer Warren Oak Felder.
  • Both went to #1 on theBillboardMainstream Top 40chart and earned Felder BMI Pop Awards in 2017 and 2018, respectively.
  • Reservoir is an independent music company based in New York City and with offices in Los Angeles, Nashville, Toronto, London, and Abu Dhabi.
  • Reservoir is the first U.S.-based publicly traded independent music company and the first female founded and led publicly traded music company in the U.S.

Saniona Initiates Phase 2b Clinical Trial of Tesomet for Hypothalamic Obesity

Retrieved on: 
Wednesday, November 17, 2021
Hypothalamus, Population, Mortality, Degenerative disease, Raymond, Non-alcoholic fatty liver disease, Type 2 diabetes, Disorder, Hypertension, Hunger, Type, Clinical trial, Depression, Prader–Willi syndrome, Lethargy, United Kingdom, Diabetes, Weight gain, Survivor, Disease, Human, CP, Heart, HO, Body mass index, Stroke, Amnesia, Somnolence, Polyphagia, Database, Patient, Metoprolol, Awareness, Vanderbilt University Medical Center, Food, OMX, Drug discovery, Attention deficit, Waist, Assistant, PWS, Craniopharyngioma, Pediatric endocrinology, Risk, FDA, Child, Brain, Obesity, Pharmaceutical industry

Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, today announced the initiation of a Phase 2b clinical trial of Tesomet in patients with hypothalamic obesity (HO).

Key Points: 
  • Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, today announced the initiation of a Phase 2b clinical trial of Tesomet in patients with hypothalamic obesity (HO).
  • The initiation of this Phase 2b clinical trial represents the culmination of the significant work and combined expertise of our clinical, regulatory, technical operations and quality teams, said Rudolf Baumgartner, M.D., Chief Medical Officer and Head of Clinical Development at Saniona.
  • We are also preparing to initiate a Phase 2b clinical trial of Tesomet in Prader-Willi syndrome before the end of the year, which, combined with our ongoing Phase 1 trial for SAN711, means our team will end the year with three rigorous clinical programs underway.
  • The Phase 2b clinical trial includes a randomized, double-blind, placebo-controlled 36-week treatment period followed by a 36-week open-label extension period.

ORYZON enrolls first patient in the US in PORTICO, a Phase IIb clinical trial with vafidemstat in Borderline Personality Disorder

Retrieved on: 
Monday, October 18, 2021
Time, Suicide, Moderate, FDA, Disease, Schizophrenia, Amnesia, GLOBE, Forward-looking statement, Public expenditure, Ageing, Mission statement, Attention deficit, Agitation, ORY, Psychotherapy, Mercado, MS, Multiple sclerosis, CNMV, Patient, Autism, Government budget balance, Arm, ASD, Prospectus, Person, AD, COVID-19, Lists of diseases, Population, Social, ISIN, BPD, PLOS, Impulsivity, Sale, ADHD, Particle-size distribution, EVOLUTION, Communication, Aggression, LSD1, FPI, Alzheimer's disease, CNS, Mouse, Genomics, Borderline personality disorder, Degenerative disease, Attention deficit hyperactivity disorder predominantly inattentive, Perception, Neuroinflammation, Personality disorder, ESCAPE, Safety, Pharmaceutical industry

PORTICO (ClinicalTrials.gov Identifier NCT04932291) is a multicenter, double-blind, randomized, placebo-controlled Phase IIb trial to evaluate the efficacy and safety of vafidemstat in BPD patients.

Key Points: 
  • PORTICO (ClinicalTrials.gov Identifier NCT04932291) is a multicenter, double-blind, randomized, placebo-controlled Phase IIb trial to evaluate the efficacy and safety of vafidemstat in BPD patients.
  • Vafidemstat offers tremendous potential to be a safe, effective, and well-tolerated treatment option in Borderline Personality Disorder, a population with high unmet medical need, but no approved safe or effective pharmacologic treatments.
  • Oryzons LSD1 program has rendered two compounds, vafidemstat and iadademstat, in Phase II clinical trials.
  • Currently, vafidemstat is in two Phase IIb trials in borderline personality disorder (PORTICO) and in schizophrenia patients (EVOLUTION).

MindAmp - Mindfulness Headphones for Meditation & Mental Wellness Announces Launch

Retrieved on: 
Tuesday, October 12, 2021
EEG, Mindfulness, Brain, Insomnia, Electronic oscillator, Relaxation, Self-control, GLOBE, Sleep, Depression, Hospital, Meditation, CEO, Anxiety, Attention deficit, Medical imaging

HONG KONG, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Today, MindAmp announced the launch of a revolutionary system for meditation and mental wellness.

Key Points: 
  • HONG KONG, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Today, MindAmp announced the launch of a revolutionary system for meditation and mental wellness.
  • Utilizing brain-sensing technology, MindAmp headphones help users quickly achieve a meditative state that helps to refocus, relieve anxiety, reduce stress, and improve sleep quality.
  • MindAmp is available now: https://www.kickstarter.com/projects/mindamp/mindamp-a-mindfulness-headp...
    MindAmp are in-ear headphones created for mindfulness with advanced sensors that guide users quickly and easily into meditation.
  • MindAmp - Mindfulness Headphones for meditation & mental wellness gives people a faster, more effective way to achieve mindful meditation for relaxation, stress relief, and sharper mental focus.

Paw for Good launches crowdfunding program to create a mutually beneficial ecosystem by transforming stray dogs into instructors for people with special needs

Retrieved on: 
Friday, September 10, 2021

The program aims to support Paw for Good to help more people in need to benefit from interacting with educational support dogs.

Key Points: 
  • The program aims to support Paw for Good to help more people in need to benefit from interacting with educational support dogs.
  • To break the stereotype that service dogs are limited to specific breeds, the team purposely chose stray dogs and train them to become educational support dogs .
  • The educational support dogs can support people with autism spectrum disorder (ASD), attention deficit and hyperactivity disorder (ADHD), depressive disorder and other disabilities.
  • Qualified educational support dogs can assist people with ASD, ADHD, depressive disorders or disabilities as well aschildren with special needs.